ADRB1 and cerebral cavernous malformation: Since neutralization of Anti-β1-AR has therapeutic effects on dilated cardiomyopathy (Müller et al., 2000), we speculate that neutralization of Anti-β1-AR may also have therapeutic implications for CCM.